ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
ASCO 2025 preview – Itovebi strengthens its first-line claim
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
